Why Dosage Form Affects Packaging Strategy

The physicochemical properties of the dosage form determine its susceptibility to degradation. Solid tablets may be vulnerable to moisture and oxidation, while liquid formulations require protection from microbial contamination, evaporation, and chemical instability. Hence, packaging material and design must align with the dosage form’s specific vulnerabilities.

Common Packaging Types for Oral Dosage Forms

Key Differences in Packaging Criteria

• Barrier Properties: Solid dosage forms need low WVTR (Water Vapor Transmission Rate); liquids require low extractables and leachables
• Seal Integrity: Critical for liquids to prevent leakage and microbial ingress
• Material Compatibility: Some liquids may react with plastics, while solids are generally inert
• Dosage Delivery: Liquids often require dosing spoons/syringes, impacting closure design

Stability Testing Focus: Solid vs. Liquid Forms

In long-term and accelerated stability studies:

• Solids: Assessed for hardness, friability, impurity growth, disintegration time
• Liquids: Evaluated for pH, microbial limits, viscosity, precipitation, color change

Packaging must prevent these changes by maintaining physical and chemical protection across ICH stability zones.

Regulatory Requirements for Packaging Selection

According to EMA and ICH Q1A(R2), packaging used in stability studies must reflect the final market configuration. This ensures that results are representative of real-world conditions. Packaging details must be captured in CTD Module 3.2.P.7:

• ✓ Container material and type
• ✓ Closure components and liners
• ✓ Description of protective features (e.g., UV barrier, desiccant use)
• ✓ Container closure integrity results

Physical Testing of Packaging During Stability

• Torque Testing (for screw caps on liquids)
• Seal Integrity Testing (for blister packs or vials)
• Moisture Uptake Evaluation (for solids in high humidity)
• Leachables and Extractables (for plastic bottles with syrups)
• Label Durability and Print Adhesion

Case Study: Packaging Selection for a Moisture-Sensitive Tablet vs. Syrup

A moisture-sensitive antihypertensive tablet was packaged in Alu-Alu blister with desiccant carton, while its pediatric syrup version was stored in amber PET bottle with child-resistant cap. The tablet remained stable across 40°C/75% RH zones for 6 months. However, the syrup exhibited color change due to poor UV barrier. Switching to amber glass prevented degradation. Lesson: Each dosage form demands custom packaging strategy validated through stability data.

Checklist: Dosage Form-Specific Packaging Evaluation

• ☑ Have the moisture and light sensitivity of the API been evaluated?
• ☑ Is the container material compatible with the dosage form?
• ☑ Are extractables and leachables under control for liquids?
• ☑ Is seal integrity verified for blister/vial/pouch?
• ☑ Are delivery devices (e.g., droppers, syringes) included in stability?
• ☑ Does the packaging match the final marketed presentation?

Stability Protocol Adaptations Based on Packaging

The stability protocol should specify storage orientations (upright for liquids), light protection measures, and specific test intervals for packaging integrity checks. For solids, blister packs require ongoing visual inspection for delamination, while liquids may need pH and viscosity tests at each pull point.

Best Practices in Packaging Documentation

To maintain GMP compliance and audit readiness:

• Include detailed packaging specifications in the stability protocol
• Ensure traceability of packaging material lots used in stability
• Archive container-closure validation reports
• Document change control for packaging-related updates

Refer to resources at GMP guidelines for documentation templates and packaging validation SOPs.

Conclusion

Solid and liquid oral dosage forms present distinct packaging challenges. Stability testing must account for these differences to select the right packaging configuration. Through rigorous evaluation of compatibility, permeability, and container closure integrity, pharmaceutical manufacturers can ensure product stability, regulatory compliance, and patient safety throughout the product’s shelf life.

References:

• ICH Q1A(R2) Stability Testing of New Drug Substances and Products
• USP Containers – Performance Testing
• FDA Guidance for Industry: Container Closure Systems
• EMA Guideline on Plastic Immediate Packaging Materials
• WHO Guidelines for Stability Testing of Pharmaceutical Products

What Is Shelf Life in the Pharmaceutical Context?

Shelf life is the time period during which a drug product retains its intended quality, efficacy, and safety under recommended storage conditions. It is determined through comprehensive stability studies, including both accelerated and long-term storage conditions, following ICH guidelines like Q1A(R2).

How Shelf Life Is Determined

• Based on the time a drug remains within approved specifications
• Derived from data gathered in real-time and accelerated stability studies
• Dependent on factors like storage conditions, formulation, and packaging
• May be reassessed upon significant changes in manufacturing or formulation

Example: A tablet formulation stored at 25°C ± 2°C/60% RH ± 5% shows consistent assay and dissolution profiles up to 24 months—thus it can be assigned a 2-year shelf life.

What Is an Expiry Date and Why Is It Important?

The expiry date is the manufacturer-assigned date after which the product should not be used. It is a regulatory requirement under guidelines such as USFDA 21 CFR Part 211, and must be printed on every pharmaceutical product’s label. It is the outer boundary of the product’s validated shelf life.

Characteristics of Expiry Date

1. Legally enforced cutoff for product usage
2. Based on shelf life data plus stability margins
3. Mandatory for commercial labeling and GMP documentation
4. Used in determining stock rotation (FEFO — First Expiry, First Out)

In contrast to shelf life, which is more technical and internal, the expiry date serves as a regulatory and public safety control measure.

Shelf Life vs. Expiry Date: A Side-by-Side Comparison

Why the Confusion Exists

The overlap between these terms originates from their dependency on the same stability data. However, misunderstanding them can lead to serious non-compliance, such as releasing expired drugs or mislabeling products. Regulatory bodies such as EMA and WHO treat expiration compliance as a critical GMP issue.

Beyond Use Date (BUD) vs Expiry Date

The term “Beyond Use Date” is often confused with the expiry date but applies mainly to compounded or repackaged products. It indicates the last date a drug should be used after it is opened or reconstituted.

For instance, a powdered antibiotic vial may have an expiry date of 2027 but a BUD of 7 days once reconstituted in sterile water.

Regulatory Perspectives on Shelf Life and Expiry

Various global agencies provide frameworks for determining and applying shelf life and expiry dates. Below are some references that pharmaceutical companies must align with:

• ICH Q1A(R2): Stability testing of new drug substances and products
• 21 CFR Part 211 (USFDA): Expiry dating and stability testing requirements
• WHO Guidelines: Provide global templates for shelf life assessment
• CDSCO India: Enforces labeling compliance per Schedule M

Companies must ensure that expiry dates are derived from scientifically justified shelf life data and that these values are reflected consistently in both internal documentation and market packaging.

Case Study: Expiry Date Compliance Audit

In a 2022 inspection, a company was cited by regulators for releasing lots past the assigned expiry date due to a misalignment between ERP stock status and printed label dates. Although the product remained within specifications, the regulatory violation led to a product recall and a warning letter.

Key Learnings

• Ensure system-printed labels match approved expiry dates
• Audit stability documentation for consistency
• Train staff on the difference between shelf life and expiry

Labeling Best Practices

To avoid compliance issues and confusion, manufacturers should:

1. Clearly mention expiry dates on all external packaging
2. Maintain internal records of shelf life justifications
3. Update shelf life/expiry info post any formulation or packaging changes
4. Ensure alignment between Certificate of Analysis and physical labels

Label formats must comply with local regulatory norms, such as those defined by CDSCO in India or the EMA in Europe.

Extending Shelf Life and Expiry Dates

Under certain conditions, shelf life or expiry may be extended based on new supporting data:

• Submission of new real-time or accelerated stability data
• Change in packaging to better barrier materials
• Reformulation that enhances stability

However, these changes require prior regulatory approval and must follow the ICH Q1E guideline on data evaluation.

Final Thoughts

Understanding the distinction between shelf life and expiry is more than semantic—it’s central to quality assurance and regulatory compliance. Pharma professionals involved in R&D, regulatory affairs, and GMP operations must treat expiry dating as a critical control measure with legal implications.

Incorrect usage of these terms can lead to adverse events, product recalls, or market bans. Conversely, clarity in their application enhances patient safety, reduces waste, and improves regulatory trust.

References:

• ICH Quality Guidelines
• FDA: Stability Testing
• EMA Scientific Guidelines
• WHO Technical Series